Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection

Slides:

Advertisements

Similar presentations

Volume 50, Issue 3, Pages (September 2006)

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 53, Issue 3, Pages (March 2008)

Volume 52, Issue 1, Pages (July 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 49, Issue 2, Pages (February 2006)

Volume 70, Issue 1, Pages (July 2016)

Volume 54, Issue 6, Pages (December 2008)

Volume 49, Issue 2, Pages (February 2006)

EAU Guidelines on Surgical Treatment of Urinary Incontinence

Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Steven A. Kaplan,

Volume 61, Issue 5, Pages (May 2012)

Volume 64, Issue 4, Pages (October 2013)

Volume 50, Issue 5, Pages (November 2006)

Volume 71, Issue 4, Pages (April 2017)

Volume 52, Issue 1, Pages (July 2007)

Volume 53, Issue 5, Pages (May 2008)

Let the Games Begin (with EAU Approval)

Prostate Cancer Epidemic in Sight?

Volume 64, Issue 4, Pages (October 2013)

Volume 45, Issue 4, Pages (April 2004)

Volume 57, Issue 5, Pages (May 2010)

Volume 46, Issue 2, Pages (August 2004)

Volume 56, Issue 1, Pages (July 2009)

Volume 63, Issue 1, Pages (January 2013)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 51, Issue 1, Pages (January 2007)

Volume 52, Issue 3, Pages (September 2007)

Volume 54, Issue 4, Pages (October 2008)

Volume 56, Issue 3, Pages (September 2009)

Volume 62, Issue 3, Pages (September 2012)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 70, Issue 3, Pages (September 2016)

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

Volume 51, Issue 2, Pages (February 2007)

P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes European Urology

Volume 64, Issue 4, Pages (October 2013)

Volume 60, Issue 1, Pages (July 2011)

Volume 55, Issue 3, Pages (March 2009)

Volume 70, Issue 1, Pages (July 2016)

Volume 52, Issue 4, Pages (October 2007)

Volume 49, Issue 6, Pages (June 2006)

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 69, Issue 2, Pages (February 2016)

Volume 61, Issue 5, Pages (May 2012)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Volume 70, Issue 6, Pages (December 2016)

Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old P. Perrin,

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

The Inside-Out Transobturator Male Sling for the Surgical Treatment of Stress Urinary Incontinence After Radical Prostatectomy: Midterm Results of a Single-Center.

Use of the National Health and Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on Cost and Prevalence of Urolithiasis in.

Volume 54, Issue 2, Pages (August 2008)

The Economic Costs of Overactive Bladder in Germany

Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl European Urology

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Testicular Cancer Variations in Time and Space in Europe

Alex Tong Long Lin, An Hang Yang, Kuang-Kuo Chen European Urology

European Urology is “Your” Journal

The Start-Up of the Platinum Journal: A Fascinating Challenge

Volume 55, Issue 3, Pages (March 2009)

Botulinum Toxin Type A Injections for Treating Neurogenic Detrusor Overactivity Combined With Low-Compliance Bladder in Patients With Spinal Cord Lesions

Understanding the Role of Botulinum Toxin A in the Treatment of the Overactive Bladder—More than Just Muscle Relaxation Apostolos Apostolidis, Axel Haferkamp,

Improving Outcomes in Patients With Refractory Idiopathic and Neurogenic Detrusor Overactivity: Management Strategies David A. Ginsberg, MD, Lynne Kolton.

Volume 52, Issue 6, Pages (December 2007)

Proposed Mechanism for the Efficacy of Injected Botulinum Toxin in the Treatment of Human Detrusor Overactivity Apostolos Apostolidis, Prokar Dasgupta,

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection Hsin-Tzu Liu, Michael B. Chancellor, Hann-Chorng Kuo European Urology Volume 56, Issue 4, Pages 700-707 (October 2009) DOI: 10.1016/j.eururo.2008.04.037 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Urinary nerve growth factor/creatinine (NGF/Cr) levels in patients with (a) idiopathic detrusor overactivity (IDO) of different urgency severity scale (USS), and (b) neurogenic detrusor overactivity (NDO) with high voiding pressure (HVP), low voiding pressure (LVP), and with autonomic dysreflexia (AD) compared with the controls. European Urology 2009 56, 700-707DOI: (10.1016/j.eururo.2008.04.037) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Urinary nerve growth factor/creatinine (NGF/Cr) levels for responders and nonresponders among patients with idiopathic detrusor overactivity (IDO) and neurogenic detrusor overactivity (NDO) at baseline and 3 mo post–BoNT-A treatment. Asterisk means statistically significant. Data are expressed as mean±standard error. European Urology 2009 56, 700-707DOI: (10.1016/j.eururo.2008.04.037) Copyright © 2008 European Association of Urology Terms and Conditions